TABLE 4

Diastolic dysfunction and cardiac troponin isoform I (cTnI) elevations in patients treated with doxorubicin- or epirubicin-based chemotherapy

Anthracycline	Δ LEVF (%)^{^a}	Diastolic Dysfunction (all)^{^b}	cTnI Elevations (all)^{^c}	Diastolic Dysfunction with cTnI Elevation
Doxorubicin	0 (−2 to +2)	14	9	7
(n = 35)		(40%)	(26%)	(20%)
Epirubicin	0 (−0.5 to 1)	10	7	2
(n = 25)		(40%)	(28%)	(8%)
	P = 0.739	P = 1.000	P = 0.874	P < 0.025

Data were analyzed by two-tailed Fisher’s exact test.
↵^a Calculated as [(LVEF T1) − (LVEF T0)].
↵^b Impaired relaxation or B-type natriuretic peptide persistent elevations in aggregate.
↵^c Any transient or persistent cTnI elevation.